Clinical research trials are studies that determine the safety and effectiveness of new drugs, devices, or treatment regimens. Each clinical trial is designed to discover new or improved ways of treating cancer. Patients who participate in clinical trials help physicians and future cancer patients determine whether a treatment is safe and effective. 

Before a patient is enrolled in a clinical research trial, studies must be approved by an Institutional Review Board (IRB), or an independent ethics committee. This entity assures the appropriate steps are taken to protect the well-being of research participants. All patients who participate in clinical trials are carefully monitored throughout the study, and typically for several months after the trial has ended, to determine safety of the treatment being tested. It is important to remember that clinical trials are completely voluntary, and patients can withdraw from a trial at any time.

Why Participate in Clinical Research?

Enrollment of patients in clinical trials is essential for progress in conquering cancer. While nationwide, only 6% of cancer patients participate in clinical trials, we are proud to announce that in our community, 15% of patients do so. When considering participating in clinical research trials, patients must learn about the benefits and risks like they would when receiving any standard treatment for their cancer. Some of the benefits of participating in clinical trials:

  • Gain access to new research treatments before they are widely available
  •  Access to study-required medical care at no cost
  • Close attention from your study team such as follow-ups regarding your care
  • Play a more active role in your healthcare
  • Opportunity to participate in research that may potential benefit others

However, participation in clinical trials can require greater time commitment as there may be more tests and visits to the clinic. Clinical trial participants may also experience unpleasant, serious, or life-threatening side effects, and your condition may not improve. Therefore, it is important to discuss if a clinical trial is right for you with your provider. While we strive to offer clinical trials that allow you to receive care close to home, we would not hesitate to refer you to an academic center if a promising clinical trial is available there.

If you are interested in learning more about clinical research studies at PCC, contact Chelsea McKean, our clinical research coordinator, at (985) 888-1523 or by email chelsea@pcclouisiana.com.



Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study (POLARIS) 

RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (ADVANCE) https://clinicaltrials.gov/ct2/show/NCT02643420

Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER) https://clinicaltrials.gov/ct2/show/NCT02953340

Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Link: https://clinicaltrials.gov/ct2/show/NCT03326674


A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy https://clinicaltrials.gov/ct2/show/NCT03151408


An Observational Study Assessing the Clinical Effectiveness of VeriStrat® and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Durvalumab in Combination with Epacadostat in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy 

A randomized parallel group phase III trial of OSE2101 as 2nd or 3rd line compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic (IV) Non-Small-Cell Lung Cancer https://clinicaltrials.gov/ct2/show/NCT02654587


Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL) https://clinicaltrials.gov/ct2/show/NCT02793583?term=TG+Therapeutics&recr=Open&cond=lymphoma&rank=

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) https://clinicaltrials.gov/ct2/show/NCT02582879

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices https://clinicaltrials.gov/ct2/show/NCT02856646

A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma https://clinicaltrials.gov/ct2/show/NCT02260804

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ https://clinicaltrials.gov/ct2/show/NCT03263026


Multiple Myeloma Patient Registry https://clinicaltrials.gov/ct2/show/NCT0318085


A Two-Stage, Open-Label Followed by Placebo-Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents https://clinicaltrials.gov/ct2/show/NCT03151304


A Prospective Registry Study to Evaluate the Efficacy of Precision Molecular Testing in the Treatment of Advanced Solid Tumors


Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) (TRUMPET)